FierceBiotech17h
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...
pulmonaryfibrosisnews14h
Blocking HIF2 protein may promote lung repair in IPF: Mouse study
Inhibiting the HIF2 protein was found to promote repair processes in a mouse model of lung injury, and may be a strategy for ...
Managed Healthcare Executive17h
The Role of Biomarkers and Biopsy for IPF and PPF
Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these ...